Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.

MLA

Hansen, A. R., et al. “Pembrolizumab for Advanced Prostate Adenocarcinoma: Findings of the KEYNOTE-028 Study.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 29, no. 8, Aug. 2018, pp. 1807–13. EBSCOhost, https://doi.org/10.1093/annonc/mdy232.

APA

Hansen, A. R., Massard, C., Ott, P. A., Haas, N. B., Lopez, J. S., Ejadi, S., Wallmark, J. M., Keam, B., Delord, J.-P., Aggarwal, R., Gould, M., Yang, P., Keefe, S. M., & Piha-Paul, S. A. (2018). Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29(8), 1807–1813. https://doi.org/10.1093/annonc/mdy232

Chicago

Hansen, A R, C Massard, P A Ott, N B Haas, J S Lopez, S Ejadi, J M Wallmark, et al. 2018. “Pembrolizumab for Advanced Prostate Adenocarcinoma: Findings of the KEYNOTE-028 Study.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29 (8): 1807–13. doi:10.1093/annonc/mdy232.